How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

March 31, 2015

Ibrutinib and ABT199 for CLL

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.

July 29, 2015

Targeted Therapies and their Impact on Melanoma

Dr. Steve O’Day works with melanoma and has seen great breakthroughs in targeted therapies and their impact on the disease.